Encainide: Difference between revisions
| Line 21: | Line 21: | ||
===Renal Dosing=== | ===Renal Dosing=== | ||
*Adult: | *Adult: Reduce to single initial daily 25mg dose; increase to 25mg b.i.d after 7 days if needed. | ||
*Pediatric: | *Pediatric: N/A | ||
===Hepatic Dosing=== | ===Hepatic Dosing=== | ||
Revision as of 00:20, 27 June 2021
Administration
- Type: Class IC antiarrhythmic (sodium channel blocker)
- Dosage Forms: Capsules (25mg or 35mg)
- Routes of Administration: PO
- Common Trade Names: Enkaid
Adult Dosing
Sustained Ventricular Tachycardia
- 25mg PO t.i.d
- May be increased to 35mg PO t.i.d after 3-5 days
Pediatric Dosing
- Safety and effectiveness in pediatrics not established
Special Populations
Pregnancy Rating
- Category B
Lactation risk
- Unknown risk to nursing infants
Renal Dosing
- Adult: Reduce to single initial daily 25mg dose; increase to 25mg b.i.d after 7 days if needed.
- Pediatric: N/A
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
- Preexisting 2nd or 3rd-degree AV block
- Preexisting right bundle branch block w/ left hemiblock
- Presence of cardiogenic shock
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion: